WHO's Product Recall Order For Shantha Biotech's Vaccine Puts Sanofi Aventis In Crisis Management Mode; Vows To Resume Supplies By End Of 2010
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - French drug maker Sanofi Aventis is faced with an unexpected crisis situation over large quantities of product recall ordered by the World Health Organization for pediatric pentavalent vaccines manufactured by its newly acquired Indian vaccines unit - Shantha Biotechnics